Zhejiang Medicine (600216) Stock Overview
Manufactures and sells life nutrition and medical products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
600216 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Zhejiang Medicine Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.56 |
| 52 Week High | CN¥16.88 |
| 52 Week Low | CN¥11.60 |
| Beta | 0.58 |
| 1 Month Change | -8.75% |
| 3 Month Change | -9.96% |
| 1 Year Change | -15.14% |
| 3 Year Change | 11.24% |
| 5 Year Change | -3.56% |
| Change since IPO | 388.07% |
Recent News & Updates
Recent updates
A Piece Of The Puzzle Missing From Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Share Price
Mar 23
Here's Why Zhejiang Medicine (SHSE:600216) Can Manage Its Debt Responsibly
Feb 07Zhejiang Medicine Co., Ltd. (SHSE:600216) Screens Well But There Might Be A Catch
Nov 22We Think That There Are Issues Underlying Zhejiang Medicine's (SHSE:600216) Earnings
Nov 01Is Zhejiang Medicine (SHSE:600216) A Risky Investment?
Sep 14What Zhejiang Medicine Co., Ltd.'s (SHSE:600216) 27% Share Price Gain Is Not Telling You
Aug 06Zhejiang Medicine (SHSE:600216) Is Reducing Its Dividend To CN¥0.15
Jul 05The Market Doesn't Like What It Sees From Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Earnings Yet
Jun 21Zhejiang Medicine's (SHSE:600216) Earnings Are Weaker Than They Seem
May 02Zhejiang Medicine (SHSE:600216) Has A Somewhat Strained Balance Sheet
Mar 29Shareholder Returns
| 600216 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.2% | -4.1% | -2.2% |
| 1Y | -15.1% | 10.7% | 17.0% |
Return vs Industry: 600216 underperformed the CN Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: 600216 underperformed the CN Market which returned 17.1% over the past year.
Price Volatility
| 600216 volatility | |
|---|---|
| 600216 Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in CN Market | 9.1% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 600216 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600216's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 5,815 | Hongwei Wang | www.zmc.top |
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and medical products in China and internationally. The company products include synthetic vitamin E, natural vitamin E, ß-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also offers fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition products.
Zhejiang Medicine Co., Ltd. Fundamentals Summary
| 600216 fundamental statistics | |
|---|---|
| Market cap | CN¥12.85b |
| Earnings (TTM) | CN¥1.24b |
| Revenue (TTM) | CN¥8.96b |
Is 600216 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600216 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.96b |
| Cost of Revenue | CN¥5.51b |
| Gross Profit | CN¥3.45b |
| Other Expenses | CN¥2.20b |
| Earnings | CN¥1.24b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.31 |
| Gross Margin | 38.47% |
| Net Profit Margin | 13.89% |
| Debt/Equity Ratio | 8.5% |
How did 600216 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/16 02:47 |
| End of Day Share Price | 2025/12/16 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zhejiang Medicine Co., Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yilin Hou | China International Capital Corporation Limited |
| Jie Yao | Citic Securities Co., Ltd. |
| Nai Di Zhao | Everbright Securities Co. Ltd. |